Trial Profile
A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 09 Mar 2023
Price :
$35
*
At a glance
- Drugs Interleukin-15 (Primary) ; Spartalizumab (Primary)
- Indications Adenocarcinoma; Gastric cancer; Malignant melanoma; Prostate cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Admune Therapeutics; Novartis; Novartis Pharmaceuticals
- 01 Mar 2023 Status changed from completed to discontinued due to business decision.
- 22 Mar 2022 Status changed from active, no longer recruiting to completed.
- 28 Jan 2022 Planned End Date changed from 24 Jan 2022 to 1 Mar 2022.